120 related articles for article (PubMed ID: 34271862)
1. Trends in survival from myeloma, 1990-2015: a competing risks analysis.
Sneyd MJ; Gray AR; Morison IM
BMC Cancer; 2021 Jul; 21(1):821. PubMed ID: 34271862
[TBL] [Abstract][Full Text] [Related]
2. Trends in myeloma incidence, mortality and survival in New Zealand (1985-2016).
Sneyd MJ; Cox B; Morison IM
Cancer Epidemiol; 2019 Jun; 60():55-59. PubMed ID: 30921701
[TBL] [Abstract][Full Text] [Related]
3. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity.
Pulte D; Redaniel MT; Brenner H; Jansen L; Jeffreys M
Leuk Lymphoma; 2014 May; 55(5):1083-9. PubMed ID: 23879201
[TBL] [Abstract][Full Text] [Related]
4. Changing survival of people with myeloma and end stage kidney disease: A cohort study using Australian and New Zealand dialysis and transplant registry 1963-2013.
Webster AC; Irish AB; Kelly PJ
Nephrology (Carlton); 2018 Mar; 23(3):217-225. PubMed ID: 28004444
[TBL] [Abstract][Full Text] [Related]
5. Regional distribution of myeloma in New Zealand.
Sneyd MJ; Gray A; Morison IM
N Z Med J; 2021 Mar; 134(1531):11-22. PubMed ID: 33767484
[TBL] [Abstract][Full Text] [Related]
6. Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM; Blacklock H; Wellard C; Spearing R; Merriman L; Poplar S; George A; Baker B; Chan H; McQuilten ZK; Wood EM; Spencer A;
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e762-e769. PubMed ID: 35501256
[TBL] [Abstract][Full Text] [Related]
7. Investigating reasons for ethnic inequalities in breast cancer survival in New Zealand.
McKenzie F; Ellison-Loschmann L; Jeffreys M
Ethn Health; 2011 Dec; 16(6):535-49. PubMed ID: 21644117
[TBL] [Abstract][Full Text] [Related]
8. Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?
Tin Tin S; Elwood JM; Brown C; Sarfati D; Campbell I; Scott N; Ramsaroop R; Seneviratne S; Harvey V; Lawrenson R
BMC Cancer; 2018 Jan; 18(1):58. PubMed ID: 29310606
[TBL] [Abstract][Full Text] [Related]
9. Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand.
Chan HSH; Milne RJ
Br J Haematol; 2020 Mar; 188(5):692-700. PubMed ID: 31584720
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
Pasqualetti P; Collacciani A; Maccarone C; Casale R
Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
[TBL] [Abstract][Full Text] [Related]
11. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.
Pulte D; Jansen L; Castro FA; Emrich K; Katalinic A; Holleczek B; Brenner H;
Br J Haematol; 2015 Oct; 171(2):189-196. PubMed ID: 26123295
[TBL] [Abstract][Full Text] [Related]
12. Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008).
Samy EF; Ross J; Bolton E; Morris EJ; Oliver SE
Leuk Lymphoma; 2015; 56(9):2660-7. PubMed ID: 25651425
[TBL] [Abstract][Full Text] [Related]
13. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups.
Libby E; Garcia D; Quintana D; Fekrazad MH; Bauman J; Ebaid A; Hromas R; Rabinowitz I; Wiggins C
Leuk Lymphoma; 2014 Dec; 55(12):2850-7. PubMed ID: 24588734
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer characteristics and survival differences between Maori, Pacific and other New Zealand women included in the Quality Audit program of Breast Surgeons of Australia and New Zealand.
Campbell I; Scott N; Seneviratne S; Kollias J; Walters D; Taylor C; Roder D
Asian Pac J Cancer Prev; 2015; 16(6):2465-72. PubMed ID: 25824782
[TBL] [Abstract][Full Text] [Related]
15. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.
Pulte D; Gondos A; Brenner H
Oncologist; 2011; 16(11):1600-3. PubMed ID: 21968047
[TBL] [Abstract][Full Text] [Related]
16. Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006.
Chihara D; Ito H; Izutsu K; Hattori M; Nishino Y; Ioka A; Matsuda T; Ito Y
Int J Cancer; 2015 Sep; 137(5):1217-23. PubMed ID: 25694231
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and survival trends in Finnish multiple myeloma patients-a nationwide real-world evidence study.
Toppila I; Miettinen T; Lassenius MI; Lievonen J; Bauer M; Anttila P
Ann Hematol; 2021 Jul; 100(7):1779-1787. PubMed ID: 33712865
[TBL] [Abstract][Full Text] [Related]
18. Different survival analysis methods for measuring long-term outcomes of Indigenous and non-Indigenous Australian cancer patients in the presence and absence of competing risks.
He VY; Condon JR; Baade PD; Zhang X; Zhao Y
Popul Health Metr; 2017 Jan; 15(1):1. PubMed ID: 28095862
[TBL] [Abstract][Full Text] [Related]
19. Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades.
Sun T; Wang S; Sun H; Wen J; An G; Li J
Leuk Lymphoma; 2018 Jan; 59(1):49-58. PubMed ID: 28595471
[TBL] [Abstract][Full Text] [Related]
20. Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).
Milano AF
J Insur Med; 2018; 47(4):203-211. PubMed ID: 30668210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
